Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1611-1615

  Cohen, Victor ^a,b   Panet Raymond, Valerie ^a,c   Sabbaghian, Nelly ^a,c   Morin, Isabelle ^a,c   Batist, Gerald ^a,b   Rozen, Rima ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINATE CALCIUM; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; THYMIDYLATE SYNTHASE; UFT;

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DNA EXTRACTION; DNA POLYMORPHISM; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENOTYPE; HAND FOOT SYNDROME; HETEROZYGOTE; HUMAN; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PREDICTION; PRIORITY JOURNAL; STOMATITIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ALLELES; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA, NEOPLASM; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS;

EID: 0037990003     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics. CA Cancer J. Clin., 50: 7-33, 2000.
2. Midgley, R., and Kerr, D. Colorectal cancer. Lancet, 353: 391-399, 1999.
3. Williams, N. S., Northover, J. M. A., Arnott, S. J. and Jass, J. R. Colorectal tumors. In: M. Peckham, H. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, pp. 1133-1168. Oxford, United Kingdom: Oxford University Press, 1995.
4. Wingo, P. A., Ries, L. A., Parker, S. L., and Heath, C. W., Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol. Biomark. Prev., 7: 271-282, 1998.
5. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., and Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol., 19: 1501-1518, 2001.
6. Pelley, R. J. Oxaliplatin: a new agent for colorectal cancer. Curr. Oncol. Rep., 3: 147-155, 2001.
7. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J., den Heijer, M., Kluijtmans, L. A., van den Heuvel, L. P., and Rozen, R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet., 10: 111-113, 1995.
8. Kawakami, K., Omura, K., Kanehira, and E. Watanabe, G. Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue. Anticancer Res., 21: 285-289, 2001.
9. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
10. Jacques, P., Bostom, A. G., Williams, R. R., Ellison, R. C., Eckfeldt, J. H., Rosenberg, I. H., Selhub, J., and Rozen, R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 93: 7-9, 1996.
11. Rustum, Y. M., Trave, F., Zakrzewski, S. F., Petrelli, N., Herrera, L., Mittelman, A., Arbuck, S. G., and Creaven, P. J. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr., 5: 165-170, 1987.
12. Peters, G. J., Hoekman, K., van Groeningen, C. J., van der Wilt, C. L., Smid, K., Meijer, S., and Pinedo, H. M. Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent. Adv. Exp. Med. Biol., 338: 613-616, 1993.
13. Rozen, R. Polymorphisms of folate and cobalamin metabolism. In: R. Carmel and D. W. Jacobsen (eds.), Homocysteine in Health and Disease, pp. 259-269. Cambridge, United Kingdom: Cambridge University Press, 2001.
14. Schwahn, B., and Rozen, R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am. J. Pharmacogenomics, 1: 189-201, 2001.
15. Ma, J., Stampfer, M. J., Christensen, B., Giovannucci, E., Hunter, D. J., Chen, J., Willett, W. C., Selhub, J., Hennekens, C. H., Gravel, R., and Rozen, R. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocysteine, and colorectal cancer risk. Cancer Epidemiol. Biomark. Prev., 8: 825-829, 1999.
16. Bagley, P. J., and Selhub, J. A. Common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. USA, 95: 13217-13220, 1998.
17. Yin, M. B., Zakrzewski, S. F., and Hakala, M. T. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol. Pharmacol., 23: 190-197, 1983.
18. Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., and Mittleman, A. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol., 5: 1559-1565, 1987.
19. Zhang, Z. G., and Rustum, Y. M. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms. Semin. Oncol., 19: 46-50, 1992.
20. Carlsson, G., Hafstrom, L. O., Spears, C. P., Gustavsson, B., and Larsson, P. A. 5-Fluorouracil (5-FU) and 5, 10-methylene tetrahydrofolate (5, 10-CH2FH4) as adjuvant therapy in an experimental rodent colon carcinoma model. Anticancer Res., 17: 3671-3674, 1997.
21. Sekhon, J., Pereira, P., Sabbaghian, N., Schievella, A. R., and Rozen, R. Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent colon carcinoma cells in vitro. Br. J. Cancer, 87: 225-230, 2002.
22. Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthetase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
23. Iacopetta, B., Grieu, F., Joseph, D., and Elsaleh, H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer, 85: 827-830, 2001.
24. Aschele, C., Debernardis, D., Casazza, S., Antonelli, G., Tunesi, G., Baldo, C., Lionetto, R., Maley, F., and Sobrero, A. Immunohistochemical quantitation of thymidylate synthase expression in colon cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol., 17: 1760-1770, 1999.
25. Paradiso, A., Simone, G., Petroni, S., Leone, B., Vallejo, C., Lacava, J., Romero, A., Machiavelli, M., DeLena, M., Allegra, C. J. and Johnston, P. G. Thymidylate synthetase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br. J. Cancer, 82: 560-567, 1982.
26. Danenberg, K., Salonga, D., Park, J. M. Leichman, C. G., Leichman, L., Johnson, M., Diasio, R. and Danenberg, P. Dihydropyrimidine dehydrogenase (DPD) and thymidylate synthetase (TS) gene expressions identify a high percentage of colorectal tumors responding to 5-fluorouracil. Proc. Am. Soc. Clin. Oncol., 17: 258a, 1998.
27. Metzger, R., Danenberg, K., Leichman, C. G., Salonga, D., Schwartz, E. L., Wadler, S., Lenz, H. J., Groshen, S., Leichman, L., and Danenberg, P. V. High basal level gene expression of thymidine phosphorolase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res., 4: 2371-2376, 1998.
28. Salonga, D., Danenberg, K., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthetase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.
29. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Jr., Stemmerman, G., Wells, J. D., Macdonald, J. S., and Meyskens, F. L., Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res., 58: 1149-1158, 1998.
30. Brett, M. C., Pickard, M., Green, B., Howel-Evans, A., Smith, D., Kinsella, A., and Poston, G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur. J. Surg. Oncol., 22: 182-185, 1996.
31. McKay, J. A., Lloret, C., Murray, G. I., Johnston, P. G., Bicknell, R., Ahmed, F. Y., Cassidy, J., and McLeod, H. L. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. Int. J. Oncol., 17: 153-158, 2000.